Cite
Reply to 'Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer'
MLA
Lifen Cao, et al. “Reply to ‘Select Cases Might Get a Benefit from Chemotherapy for Stage I PT1aN0M0 HER2+ Breast Cancer.’” CancerREFERENCES, vol. 128, no. 16, May 2022. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e704bf5551a8f7b582c2c4aa060c32ac&authtype=sso&custid=ns315887.
APA
Lifen Cao, Nickolas Stabellini, Amanda L. Amin, & Alberto J. Montero. (2022). Reply to “Select cases might get a benefit from chemotherapy for Stage I pT1aN0M0 HER2+ breast cancer.” CancerREFERENCES, 128(16).
Chicago
Lifen Cao, Nickolas Stabellini, Amanda L. Amin, and Alberto J. Montero. 2022. “Reply to ‘Select Cases Might Get a Benefit from Chemotherapy for Stage I PT1aN0M0 HER2+ Breast Cancer.’” CancerREFERENCES 128 (16). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....e704bf5551a8f7b582c2c4aa060c32ac&authtype=sso&custid=ns315887.